Recombinant Human CCL27 (CTACK) (carrier-free)

CCL27 is highly expressed in skin where it is constitutively produced by keratinocytes. CCL27 binds to CCR10 (shared with CCL28) which is expressed on melanocytes, fibroblasts, and dermal microvascular endothelial cells. The interaction of CCL27 with CCR10 has a main role in skin homeostasis and inflammation. It has been described that more than 90% of the lymphocytes in the skin of patients with psoriasis, atopic dermatitis, and allergic-contact dermatitis express CCR10. In melanoma, CCR10 increases the ability of neoplastic cells to grow, invade tissues, disseminate to lymph nodes, and escape host immune responses. Also, it has been described that human skin tumors elude T cell-mediated antitumor immune responses by down-regulating the expression of CCL27. Interestingly, this down-regulation is mediated by EGFR signaling. In addition, CCL27 upregulation in melanoma cells impairs tumor growth due to the recruitment and accumulation of T cells and natural killer cells at tumor sites, resulting in enhanced antitumor immune responses.